Sign up
Pharma Capital
EPIC: REDX
Market: AIM
52-week High/Low: 28.63p / 3.50p
Sector: Pharma & Biotech
Market Cap: 10.88M
Website: RedxPharma.com

Redx Pharma was formed in 2010 and is an established drug discovery and development company based at Alderley Park. The Group’s work has been endorsed by partnerships with global pharmaceutical companies, and focuses on the development of proprietary, small molecule therapeutics to address areas of high unmet medical need in cancer and fibrosis.

Redx Pharma Plc

RedxPharma.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Redx Pharma Plc

Redx Pharma Plc Snapshot

Drug discovery and development business creating high value cancer and fibrosis therapeutics
Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class.

Pioneering transformational drug discovery and development in the area of cancer Novel drugs for a precision medicine approach to cancer therapy
Our strategy in cancer

Genetic mutations causing uncontrolled cell division can lead to cancer. Scientists continue to make great advances in the treatment of cancer, however it remains a leading cause of death worldwide, accounting for 1 in 6 deaths globally.

Building on our drug discovery capability in cancer, our scientists are developing cutting edge new therapies to improve cancer patient outcomes. We believe this is best achieved through the discovery and development of highly selective small molecule drugs, in the areas of genetically targeted therapy and Immuno-oncology.

To read further click here.

Pioneering transformational drug discovery and development in the area of fibrosis 
Our strategy in fibrosis

Fibrosis is an internal scarring process, which can occur in response to injury, where excess connective tissue is deposited in an organ or tissue – thereby impairing its function. Most chronic inflammatory diseases will result in fibrosis, with progressive injury resulting in organ failure. Fibrotic disease can occur in nearly any tissue in the body and contributes to 45% of deaths in the developed world. Solid organ fibrosis can occur as a result of many different diseases, for example inflammatory bowel disease. Current therapeutic options are limited for these chronic and often life-threatening diseases.

Redx’s experienced team of scientists have considerable expertise in understanding the molecular mechanisms underlying fibrosis and hence which druggable targets to focus on. We are developing cutting edge therapies that aim to stop and reverse the formation of fibrotic tissue. By targeting pathways involved in the progression of these devastating diseases these drugs will be disease modifying rather than simply providing symptomatic relief.

To read further click here.

Ian Ross, Chairman
Iain Ross was appointed Non-Executive Chairman of Redx in May 2017 assuming the role of Executive Chairman in October 2017. In addition, he is Chairman of e-Therapeutics plc (AIM:ETX) and Novogen Ltd (ASX: NRT / NASDAQ:NVGN) and also a Non-Executive Director of Anatara LifeSciences Ltd (ASX:ANR). He is a qualified Chartered Director, and a Former Vice Chairman of the Council of Royal Holloway, London University.

Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc. He has advised banks and private equity groups on numerous company turnarounds. These include as CEO of Quadrant Healthcare taking the Company public, signing numerous collaborations before selling the business to Elan in 2001. As Chairman and Chief Executive Officer, at Allergy Therapeutics, he re-structured the Company Balance Sheet to position Allergy Therapeutics as a virtually debt free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics Plc (formerly SR Pharma plc), he turned the business around through M&A and established collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc. He continues to consult for private equity groups on biotech & technology company turnarounds.


Lisa Anson, Chief Executive Offier
Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed 1 June 2018.

Lisa has been President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Lisa has held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams.

Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. Upon graduating she joined KPMG in London as a management consultant and then moved to California where she worked for Salick Health Care (now Aptium), a California based cancer disease management company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a business development manager.

Lisa is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.


Dr Bernhard Kirschbaum, Non-Executive Director

Bernhard Kirschbaum joined the Board in January 2016. Bernhard has over 25 years’ experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company’s R&D portfolio, with over 70 programs, doubling the number of phase II assets in this period. Dr Kirschbaum is currently Chairman of Protagen Diagnostics and a board member of BioMedX and OMEICOS Therapeutics.


Peter Presland, Non-executive Director

Peter Presland has nearly 45 years’ experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King’s College, London, he also qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc, a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the youngest ever PLC Director when appointed Group Finance Director at the age of 34. He was promoted to become Heath’s Group Chief Executive in 1990, and in 1996, he devised the demerger of C E Heath’s computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Executive Chairman. Shareholders doubled their money in three years. Since 2001, Peter has pursued a portfolio non-executive career. These appointments include the Chairmanship in 2003 of LINK, the UK ATM network, where he led a major corporate governance change and completed the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. From 2012 to 2015, he served as Chairman of the Audit and Governance Committee of East Kent Hospitals NHS Trust and has recently joined the Audit, Governance and Nominations Committee of The Lord’s Taverners, a high-profile charity.

 

Mr Dominic Jackson, CFO
Dominic has worked in private equity since 2007 (DIC Europe, Merrill Lynch Global Private Equity and latterly for multiple financial sponsors) and in M&A prior to that (Deutsche Bank, PricewaterhouseCoopers). He has been seconded into portfolio companies as CFO on numerous occasions to stabilise distressed core businesses and implement value initiatives.

Within the healthcare space, Dominic has completed a variety of deals as principal including the £450m sale of IDH to Carlyle, the carve-out and €485m sale of Euromedic’s Dialysis division to Fresenius Medical Care (14x EBITDA), and the refinancing and syndication of €565m term debt tranches within Euromedic’s diagnostic imaging business. Dominic has extensive situational distressed experience having acquired Peverel (UK’s largest property manager, now Knight Square) for £65m out of administration following which his secondment into the business contributed to its successful turnaround and sequential refinancings with Electra Partners and RBS. He was also heavily involved in the private equity portfolio of a recent landmark bank work-out as well as the $8bn restructuring of a Middle Eastern sovereign wealth fund.

Dominic qualified as a Chartered Accountant with PricewaterhouseCoopers and is a member of the Chartered Institute of Securities and Investment and the Institute for Turnaround.

Block 33
Mereside, Alderley Park
Alderley Edge
Macclesfield
SK10 4TG

 

Business Development

Nicholas Adams
Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

01625 238 972

 

Investor Relations

Karl Hård
Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

+44 7491 651 406

 

Human Resources

Redx Pharma HR
PO Box 707
Wakefield
WF1 9PJ

01924 566 080

 

Financial PR

Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

020 3709 5700

 

Public Relations

Chris Hulme
Influential
5th Floor, Oxford Place
61 Oxford Street
Manchester
M1 6EQ

0161 804 1400

Cantor Fitzgerald Europe
One Churchill Place
London E14 5RB, UK

 

Joint Broker
WG Partners LLP
85 Gresham Street
London EC2V 7NQ, UK

Auditor
RSM UK Audit LLP
3 Hardman Street
Manchester M3 3HF, UK

Financial Communications Advisor
FTI Consulting
200 Aldersgate Street
London EC1A 4HD

Legal Advisors
Covington and Burling LLP
265 Strand
London WC2R 1BH, UK

 

DWF LLP
1 Scott Place
2 Hardman Street
Manchester M3 3AA, UK

Registrar
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA, UK

 

View full REDX profile View Profile
View All

Columns Including REDX

VIEW ALL

Market Reports Including REDX

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.